ClinicalTrials.gg
CompletedNCT07223073Updated Oct 31, 2025

A Clinical Study Conducted in the Bangkok, Thailand Area, to Investigate the Clinical Efficacy of a New Toothpaste

A Phase 3 interventional study of 0.454% stannous fluoride and 0.76% sodium monofluorophosphate in Oral Malodor, sponsored by Colgate Palmolive. Completed at 1 site in Thailand. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-31.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 10 months ago, and no results have been posted to the registry.
  • Registered 7 years 10 months after the study started (first participant enrolled Dec 2017, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To investigate the clinical efficacy of a new toothpaste containing 0.454% stannous fluoride as compared to a regular fluoride toothpaste containing 0.76% sodium monofluorophosphate on oral malodor reduction via organoleptic scores 12 hours post-brushing overnight after 3 weeks of twice a day (morning and evening) product use.

02

Conditions studied

  • Oral Malodor
03

In context

Lead sponsor

Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults between the ages of 18-70 (inclusive)
  • Subjects must be in general good health
  • Subjects must be in good oral health based on self-assessment
  • Subjects must be available for the duration of the study for all time point assessments
  • Subjects were required to possess a minimum of 20 natural uncrowned teeth (excluding third molars)
  • Subjects were required to sign an form
  • No known history or allergies to personal care/consumer products or their ingredients.

Exclusion criteria

Exclusion Criteria:

  • Participated in any other oral clinical studies during the duration of this study
  • Had full or partial (upper or lower) dentures
  • Women who are pregnant or lactating (breast feeding)
  • Use of tobacco products, (5) History of allergies to common mouthwash ingredients
  • Use of phenolic flavored products, such as mint flavored candies and chewing gum the morning of the study of during the sampling periods
  • Immune compromised individuals (, AIDS, immune suppressive drug therapy
  • Individuals who, due to medical conditions cannot go without eating or drinking for the post use treatment evaluation time points (6-hours plus overnight).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Test 1 toothpaste

    Drug: 0.454% stannous fluoride

  • Active comparator
    Test 2 Toothpaste

    Drug: 0.76% sodium monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Organoleptic scores for each treatment group

    For each subject at each evaluation time point, the hedonic breath-odor scores assigned by the four (4) judges were averaged to yield a single subject-wise score. Statistical analyses were performed on these average organoleptic hedonic scores.

    Time frame: Baseline, 12 hours post brushing and 3 weeks

07

Study locations

1 site
  • M U International Oral Science Research, Ltd.
    Bangkok, Bangkok 10250, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
Dec 21, 2017
Primary completionActual
Jan 12, 2018
CompletionActual
Jan 12, 2018
Last update
Oct 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223073
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Dec 21, 2017
Primary completion
Jan 12, 2018
Completion
Jan 12, 2018
Last update
Oct 31, 2025

Study contacts

Terdphong Triratana, DDS
principal investigator · Mahidol University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion